Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation

Blood

Volumn 115, Issue 25, 2010, Pages 5241-5248

  Zaitsev, Sergei ^a   Spitzer, Dirk ^b   Murciano, Juan Carlos ^c   Ding, Bi Sen ^a   Tliba, Samira ^a   Kowalska, M Anna ^d   Marcos Contreras, Oscar A ^c   Kuo, Alice ^a   Stepanova, Victoria ^a   Atkinson, John P ^b   Poncz, Mortimer ^d   Cines, Douglas B ^a   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ENZYME PRECURSOR; GLYCOPHORIN A; HYBRID PROTEIN; PLASMINOGEN ACTIVATOR; PROUROKINASE; THROMBIN; FIBRINOLYTIC AGENT; PRODRUG; RECOMBINANT PROTEIN; SARUPLASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTERY THROMBOSIS; ARTICLE; BIOCOMPATIBILITY; BLOOD; BLOOD CLOTTING; CENTRAL NERVOUS SYSTEM; CIRCULATION; CLEARANCE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; ERYTHROCYTE; FIBRINOLYSIS; LIFE; MOLECULAR WEIGHT; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; ZYMOGRAPHY; ANIMAL; DRUG DELIVERY SYSTEM; HUMAN; TIME;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME PRECURSORS; ERYTHROCYTES; FIBRINOLYTIC AGENTS; HUMANS; MICE; PRODRUGS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; THROMBOSIS; TIME FACTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77954687045     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-261610     Document Type: Article

References (43)

1. Holvoet P, Laroche Y, Stassen JM, et al. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Blood. 1993;81(3):696-703. (Pubitemid 23040862)
2. Topol EJ, Morris DC, Smalling RW, et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol. 1987;9(6):1205-1213. (Pubitemid 17083516)
3. Runge MS, Harker LA, Bode C, et al. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. 1996;94(6):1412-1422. (Pubitemid 26307274)
4. Collen D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation. 1996;93(5):857-865. (Pubitemid 26074821)
5. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 1995;92(7):1883-1890.
6. Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, Muzykantov VR. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol. 2003;21(8):891-896. (Pubitemid 36936194)
7. Ganguly K, Krasik T, Medinilla S, et al. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther. 2005;312(3):1106-1113. (Pubitemid 40293770)
8. Danielyan K, Ganguly K, Ding BS, et al. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation. 2008;118(14):1442-1449.
9. Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109(2):280-287. (Pubitemid 30350706)
10. Spitzer D, Unsinger J, Bessler M, Atkinson JP. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol. 2004;40(13):911-919. (Pubitemid 38077035)
11. Furthmayr H, Marchesi VT. Subunit structure of human erythrocyte glycophorin A. Biochemistry. 1976;15(5):1137-1144.
12. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932-943. (Pubitemid 35477371)
13. Yang WP, Goldstein J, Procyk R, Matsueda GR, Shaw SY. Design and evaluation of a thrombinactivable plasminogen activator. Biochemistry. 1994;33(8):606-612.
14. Ding BS, Gottstein C, Grunow A, et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood. 2005;106(13):4191-4198. (Pubitemid 41775926)
15. Ding BS, Hong N, Murciano JC, et al. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood. 2008;111(4):1999-2006. (Pubitemid 351451510)
16. Wang YX, Martin-McNulty B, Freay AD, et al. Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol. 2001;159(4):1455-1464. (Pubitemid 32947975)
17. Schwartz RS, Rybicki AC, Nagel RL. Molecular cloning and expression of a chloride channel-associated protein pICln in human young red blood cells: association with actin. Biochem J. 1997;327(pt 2):609-616. (Pubitemid 27477843)
18. Zaitsev S, Danielyan K, Murciano JC, et al. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood. 2006;108(6):1895-1902. (Pubitemid 44403687)
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329(10):673-682.
20. Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Am J Cardiol. 2006;98(9):1125-1131. (Pubitemid 44596219)
21. Ganguly K, Goel MS, Krasik T, et al. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther. 2006;316(3):1130-1136. (Pubitemid 43348697)
22. Ganguly K, Murciano JC, Westrick R, Leferovich J, Cines DB, Muzykantov VR. The glycocalyx protects erythrocyte-bound tissue type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther. 2007;321(1):158-164. (Pubitemid 46456958)
23. Armstead WM, Ganguly K, Kiessling JW, et al. Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab. 2009;29(8):1463-1474.
24. Markland W, Pollock D, Livingston DJ. Structure-function analysis of tissue-type plasminogen activator by linker-insertion, point and deletion mutagenesis. Protein Eng. 1989;3(2):117-125. (Pubitemid 20055087)
25. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost. 1995;74(1):387-390.
26. Skriver L, Nielsen LS, Stephens R, Dano K. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem. 1982;124(2):409-414. (Pubitemid 12064803)
27. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem. 1986;261(8):3486-3489. (Pubitemid 17200642)
28. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991;266(8):5147-5152. (Pubitemid 21909471)
29. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem. 1994;269(13):9416-9419.
30. List K, Jensen ON, Bugge TH, et al. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of prourokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry. 2000;39(3):508-515. (Pubitemid 30077624)
31. Spitzer D, Unsinger J, Mao D, Wu X, Molina H, Atkinson JP. In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. J Immunol. 2005;175(11):7763-7770. (Pubitemid 41713476)
32. Spitzer D,Wu X, Ma X, Xu L, Ponder KP, Atkinson JP. Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy. J Immunol. 2006;177(8):4953-4956. (Pubitemid 44527562)
33. Liu JN, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry. 1992;31(27):6311-6317.
34. Nusrat AR, Chapman HA Jr. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest. 1991;87(3):1091-1097.
35. Ugwu F, Van Hoef B, Bini A, Collen D, Lijnen HR. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry. 1998;37(20):7231-7236. (Pubitemid 28235204)
36. Bdeir K, Kuo A, Sachais BS, et al. The kringle stabilizes urokinase binding to the urokinase receptor. Blood. 2003;102(10):3600-3608. (Pubitemid 37409377)
37. Higazi A al-R, Cines D. Regulation of single chain urokinase by small peptides. Thromb Res. 1996;84(4):243-252.
38. Barnathan ES, Kuo A, Kariko K, et al. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. Blood. 1990;76(9):1795-1806.
39. Husain SS. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry. 1991;30(23):5797-5805.
40. Urano T, de Serrano VS, Gaffney PJ, Castellino FJ. The activation of human [Glu1]plasminogen by human single-chain urokinase. Arch Biochem Biophys. 1988;264(1):222-230.
41. Zhang L, Strickland DK, Cines DB, Higazi AA. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem. 1997;272(43):27053-27057. (Pubitemid 27452660)
42. Gersh KC, Zaitsev S, Muzykantov V, Cines DB, Weisel JW. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound versus free fibrinolytics [published online ahead of print February 9, 2010]. J Thromb Haemost. doi: 10.1111/j.1538-7836.2010.03802.x.
43. Runge MS, Quertermous T, Zavodny PJ, et al. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci U S A. 1991;88(22):10337-10341. (Pubitemid 21915830)